Search

Your search keyword '"Leal, Alexis D."' showing total 147 results
Start Over Author "Leal, Alexis D."
147 results on '"Leal, Alexis D."'

1. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Author

Pant, Shubham, Wainberg, Zev A., Weekes, Colin D., Furqan, Muhammad, Kasi, Pashtoon M., Devoe, Craig E., Leal, Alexis D., Chung, Vincent, Basturk, Olca, VanWyk, Haley, Tavares, Amy M., Seenappa, Lochana M., Perry, James R., Kheoh, Thian, McNeil, Lisa K., Welkowsky, Esther, DeMuth, Peter C., Haqq, Christopher M., and O’Reilly, Eileen M.

Published
2024
Full Text
View/download PDF

2. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

Author

Jimeno, Antonio, Baranda, Joaquina, Iams, Wade T., Park, Jong Chul, Mita, Monica, Gordon, Michael S., Taylor, Matthew, Dhani, Neesha, Leal, Alexis D., Neupane, Prakash, Eng, Cathy, Yeku, Oladapo, Mita, Alain, Moser, Justin C., Butler, Marcus, Loughhead, Scott M., Jennings, Julia, Miselis, Nathan R., Ji, Rui-Ru, Nair, Nitya, Kornacker, Martin, Zwirtes, Ricardo F., Bernstein, Howard, and Sharei, Armon

Published
2023
Full Text
View/download PDF

5. Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens

Author

Leal, Alexis D, Van Houten, Holly, Sangaralingham, Lindsey, Freedman, Rachel A, Jemal, Ahmedin, Neuman, Heather B, Haddad, Tufia C, Mutter, Robert W, Keegan, Theresa HM, Mougalian, Sarah S, Loprinzi, Charles L, Gross, Cary P, Shah, Nilay, and Ruddy, Kathryn J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Breast Cancer, Health Services, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cancer Survivors, Chemotherapy, Adjuvant, Cohort Studies, Cyclophosphamide, Docetaxel, Doxorubicin, Female, Humans, Insurance Claim Review, Lymph Node Excision, Mastectomy, Middle Aged, Office Visits, Paclitaxel, Breast neoplasms, Follow-up, Health care use, Outpatient, Toxicity, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundTreatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adjuvant chemotherapy regimens to better understand how differences in toxicities between regimens might affect health care use.Materials and methodsWe analyzed administrative claims data from a US commercial insurance database (OptumLabs) to identify women who received adjuvant doxorubicin/cyclophosphamide (AC), AC followed or preceded by docetaxel or paclitaxel (AC-T), AC concurrent with docetaxel or paclitaxel (TAC), or docetaxel/cyclophosphamide (TC) between 2008 and 2014. We compared mean numbers of visits per patient (adjusted for age, race/ethnicity, region, year, surgery type, radiation, chronic conditions, and previous hospitalizations) across the different regimens (TC = reference) for 12 months, starting 4 months after the end of chemotherapy.ResultsIn 6247 eligible patients, the mean adjusted number of outpatient visits per patient was significantly higher in patients who received AC-T (8.1) or TAC (7.3) than TC (6.5) or AC (6.0; P < .001 for comparisons of AC-T and TAC with TC), primarily because of differences in Medical Oncology visits. Approximately 40% did not see a primary care provider at all during this time frame.ConclusionsAC-T and TAC are associated with more subsequent outpatient visits than TC. Visits to primary care providers are infrequent during the year after completion of chemotherapy.

Published
2018

6. A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors

Author

Davis, S. Lindsey, primary, Messersmith, Wells A., additional, Purcell, W. Thomas, additional, Lam, Elaine T., additional, Corr, Bradley R., additional, Leal, Alexis D., additional, Lieu, Christopher H., additional, O’Bryant, Cindy L., additional, Smoots, Stephen G., additional, Dus, Evan D., additional, Jordan, Kimberly R., additional, Serkova, Natalie J., additional, Pitts, Todd M., additional, and Diamond, Jennifer R., additional

Published
2024
Full Text
View/download PDF

7. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL)

Author

Hawkins, Hayley J., primary, Yacob, Betelehem W., additional, Brown, Monica E., additional, Goldstein, Brandon R., additional, Arcaroli, John J., additional, Bagby, Stacey M., additional, Hartman, Sarah J., additional, Macbeth, Morgan, additional, Goodspeed, Andrew, additional, Danhorn, Thomas, additional, Lentz, Robert W., additional, Lieu, Christopher H., additional, Leal, Alexis D., additional, Messersmith, Wells A., additional, Dempsey, Peter J., additional, and Pitts, Todd M., additional

Published
2024
Full Text
View/download PDF

9. Pathological Features Associated with Lymph Node Disease in Patients with Appendiceal Neuroendocrine Tumors.

Author

Rodriguez Franco, Salvador, Ghaffar, Sumaya Abdul, Jin, Ying, Weiss, Reed, Hamermesh, Mona, Khomiak, Andrii, Sugawara, Toshitaka, Franklin, Oskar, Leal, Alexis D., Lieu, Christopher H., Schulick, Richard D., Del Chiaro, Marco, Ahrendt, Steven, McCarter, Martin D., and Gleisner, Ana L.

Subjects
LYMPH nodes, RISK assessment, DESCRIPTIVE statistics, CANCER patients, PATIENT care, METASTASIS, NEUROENDOCRINE tumors, PHYSICIAN practice patterns, TUMOR classification, DISEASE risk factors
Abstract

Simple Summary: This study investigated whether certain features of appendiceal neuroendocrine tumors, beyond tumor size, can help predict the risk of lymph node invasion. We reviewed over 5000 cases from a national cancer database and found that in addition to the size of the tumor, lymphovascular invasion is a very strong risk predictor. Interestingly, we discovered that the growth of the tumor into deeper layers, which is usually considered a critical factor in evaluating small tumors, did not significantly affect the risk of lymph node invasion. This study aims to refine how we assess the risk of local spreading, encouraging a more tailored surgical approach, which could prevent unnecessary procedures and better focus on what is truly necessary for patient care. This study aimed to evaluate the role of pathological features beyond tumor size in the risk of lymph node metastasis in appendiceal neuroendocrine tumors. Analyzing data from the national cancer database, we found that among 5353 cases, 18.8% had lymph node metastasis. Focusing on tumors smaller than 2 cm, a subject of considerable debate in treatment strategies, we identified lymphovascular invasion as one of the strongest predictors of lymph node disease. Interestingly, extension into the subserosa and beyond, a current factor in the staging system, was not a strong predictor. These findings suggest that careful interpretation of pathological features is needed when selecting therapeutic approaches using current staging systems. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Abstract C092: T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile lymph node targeted mutant KRAS vaccine

Author

Wainberg, Zev A., primary, Pant, Shubham, additional, Weekes, Colin D., additional, Furqan, Muhammad, additional, Kasi, Pashtoon M., additional, Devoe, Craig E., additional, Leal, Alexis D., additional, Chung, Vincent, additional, Perry, James R., additional, Seenappa, Lochana, additional, McNeil, Lisa K., additional, Welkowsky, Esther, additional, DeMuth, Peter C., additional, Haqq, Christopher M., additional, and O'Reilly, Eileen M., additional

Published
2024
Full Text
View/download PDF

12. FIGURE 4 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

13. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, additional, Atif, Shaikh M., additional, Dinarello, Alberto, additional, Azam, Tania, additional, Alula, Kibrom M., additional, Piper, Miles, additional, Lieu, Christopher H., additional, Lentz, Robert W., additional, Leal, Alexis D., additional, Bagby, Stacey M., additional, Messersmith, Wells A., additional, Karam, Sana D., additional, Dinarello, Charles A., additional, Pitts, Todd M., additional, and Marchetti, Carlo, additional

Published
2023
Full Text
View/download PDF

14. FIGURE 1 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

15. Data from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

16. FIGURE 3 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

17. FIGURE 8 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

18. FIGURE 6 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

19. FIGURE 5 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure S6 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

21. FIGURE 2 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

22. FIGURE 7 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

23. Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models

Author

Lang, Julie, primary, Leal, Alexis D., additional, Marín-Jiménez, Juan A., additional, Hartman, Sarah J., additional, Shulman, Jeremy, additional, Navarro, Natalie M., additional, Lewis, Matthew S., additional, Capasso, Anna, additional, Bagby, Stacey M., additional, Yacob, Bethlehem W., additional, MacBeth, Morgan, additional, Freed, Brian M., additional, Eckhardt, S. Gail, additional, Jordan, Kimberly, additional, Blatchford, Patrick J., additional, Pelanda, Roberta, additional, Lieu, Christopher H., additional, Messersmith, Wells A., additional, and Pitts, Todd M., additional

Published
2022
Full Text
View/download PDF

27. Additional file 3 of ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

Author

Davis, S. Lindsey, Hartman, Sarah J., Bagby, Stacey M., Schlaepfer, Marina, Yacob, Betelehem W., Tse, Tonia, Simmons, Dennis M., Diamond, Jennifer R., Lieu, Christopher H., Leal, Alexis D., Cadogan, Elaine B., Hughes, Gareth D., Durant, Stephen T., Messersmith, Wells A., and Pitts, Todd M.

Abstract

Additional file 3. ARRIVE guidelines checklist referencing details of animal experiments as outlined in the manuscript.

Published
2022
Full Text
View/download PDF

28. Additional file 1 of ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

Author

Davis, S. Lindsey, Hartman, Sarah J., Bagby, Stacey M., Schlaepfer, Marina, Yacob, Betelehem W., Tse, Tonia, Simmons, Dennis M., Diamond, Jennifer R., Lieu, Christopher H., Leal, Alexis D., Cadogan, Elaine B., Hughes, Gareth D., Durant, Stephen T., Messersmith, Wells A., and Pitts, Todd M.

Abstract

Additional file 1: Supplemental Table 1. Prototypical DNA Damage Repair Mutations in CRC Models Utilized in this Study. Supplemental Figure 1. Effect of AZD0156 and SN38 on proliferation in CRC cell lines. AZD0156 dose 50nM, SN38 dose 10nM. Percent confluence relative to vehicle at 120 hours as assessed by Incucyte ZOOM. Supplemental Figure 2. Effect of AZD0156 and SN38 on proliferation in additional CRC cell lines. Percent confluence relative to vehicle as measured by IncuCyte ZOOM™ over 120 hours in an additional 8 CRC cell lines treated with AZD0156 50 nM and 100 nM and SN38 10 nM, alone and in combination. Supplemental Figure 3. Statistical evaluation of synergy based on Bliss independence. Comparison of single agent and combination effect as assessed by Incucyte ZOOM™ to Bliss independence, derived from individual groups by computing survival fraction under the assumption that treatments act independently, as per Demidenko E, et al. [12]. Supplemental Figure 4. In vivo effects of AZD0156 and chemotherapy in CRC PDX models. (A) Effect of AZD0156, irinotecan, and 5FU, alone and in combination in the CRC026 and CRC102 PDX models. Additional treatment groups added to data provided in Figure 5 of the main text. Doses of irinotecan and 5FU were reduced in single-agent and combination arms at day 11 in the CRC026 model due to its sensitivity to these single agents. (B) Specific Growth Rates of CRC026 and CRC102. Supplemental Figure 5. (A) Effect of AZD0156, irinotecan, and 5FU, alone and in combination in additional CRC001 and CRC042 PDX models. (B) Specific growth rates of CRC001 and CRC042.

Published
2022
Full Text
View/download PDF

29. Additional file 2 of ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

Author

Davis, S. Lindsey, Hartman, Sarah J., Bagby, Stacey M., Schlaepfer, Marina, Yacob, Betelehem W., Tse, Tonia, Simmons, Dennis M., Diamond, Jennifer R., Lieu, Christopher H., Leal, Alexis D., Cadogan, Elaine B., Hughes, Gareth D., Durant, Stephen T., Messersmith, Wells A., and Pitts, Todd M.

Abstract

Additional file 2. Original, full-length images from immunoblotting, corresponding to cropped images shown in Fig. 4.

Published
2022
Full Text
View/download PDF

33. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma

Author

Hartman, Sarah J., primary, Bagby, Stacey M., additional, Yacob, Betelehem W., additional, Simmons, Dennis M., additional, MacBeth, Morgan, additional, Lieu, Christopher H., additional, Davis, S. Lindsey, additional, Leal, Alexis D., additional, Tentler, John J., additional, Diamond, Jennifer R., additional, Eckhardt, S. Gail, additional, Messersmith, Wells A., additional, and Pitts, Todd M., additional

Published
2021
Full Text
View/download PDF

34. Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers

Author

Kastelowitz, Noah, primary, Marsh, Megan D., additional, McCarter, Martin, additional, Meguid, Robert A., additional, Bhardwaj, Narine Wandrey, additional, Mitchell, John D., additional, Weyant, Michael J., additional, Scott, Christopher, additional, Schefter, Tracey, additional, Stumpf, Priscilla, additional, Leong, Stephen, additional, Messersmith, Wells, additional, Lieu, Christopher, additional, Leal, Alexis D., additional, Davis, S. Lindsey, additional, Purcell, William T., additional, Kane, Madeleine, additional, Wani, Sachin, additional, Shah, Raj, additional, Hammad, Hazem, additional, Edmundowicz, Steven, additional, and Goodman, Karyn A., additional

Published
2021
Full Text
View/download PDF

36. Abstract 6647: Sensitizing microsatellite stable colorectal cancer to immune checkpoint therapy utilizing Wnt pathway inhibition

Author

Bagby, Stacey M., primary, Hartman, Sarah J., additional, Navarro, Natalie M., additional, Yacob, Betelehem W., additional, Shulman, Jeremy, additional, Barkow, Jessica, additional, Lieu, Christopher H., additional, Davis, S. Lindsey, additional, Leal, Alexis D., additional, Messersmith, Wells A., additional, Minic, Angela, additional, Jordan, Kimberly R., additional, Lang, Julie, additional, and Pitts, Todd M., additional

Published
2020
Full Text
View/download PDF

37. Abstract 6387: Therapeutic targeting of lipid oxidation and apoptosis in pancreatic ductal adenocarcinoma

Author

Hartman, Sarah J., primary, Nadales, Nathalie, additional, Bagby, Stacey M., additional, Yacob, Betelehem W., additional, Gittleman, Brian L., additional, Estrada-Bernal, Adriana, additional, Le, Anh T., additional, Lieu, Christopher H., additional, Davis, S. Lindsey, additional, Leal, Alexis D., additional, Diamond, Jennifer R., additional, Messersmith, Wells A., additional, Schlaepfer, Isabel R., additional, and Pitts, Todd M., additional

Published
2020
Full Text
View/download PDF

38. Abstract A109: Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint inhibition by immune modulation in humanized mouse models

Author

Lang, Julie, primary, Leal, Alexis D., additional, Hartmann, Sarah J., additional, Marin-Jimenez, Juan, additional, Shulman, Jeremy, additional, Capasso, Anna, additional, Bagby, Stacey M., additional, Yacob, Bethlehem W., additional, Blanchford, Patrick J., additional, Lieu, Christopher H., additional, Messersmith, Wells A., additional, and Pitts, Todd M., additional

Published
2020
Full Text
View/download PDF

39. Abstract 4720: Ataxia telangiectasia mutated (ATM) kinase inhibitor AZD0156 in combination with 5-fluorouracil and irinotecan in preclinical models of colorectal cancer

Author

Davis, S. Lindsey, primary, Schlaepfer, Marina I., additional, Bagby, Stacey M., additional, Hartman, Sarah J., additional, Yacob, Betelehem W., additional, Tse, Tonia, additional, Simmons, Dennis M., additional, Diamond, Jennifer R., additional, Lieu, Christopher H., additional, Leal, Alexis D., additional, Cadogan, Elaine B., additional, Hughes, Gareth D., additional, Durant, Stephen T., additional, Messersmith, Wells A., additional, and Pitts, Todd M., additional

Published
2019
Full Text
View/download PDF

41. Abstract 1315: Combination of Wee1 inhibition with targeted and standard chemotherapy in preclinical models of pancreatic ductal adenocarcinoma

Author

Hartman, Sarah J., primary, Bagby, Stacey M., additional, Yacob, Betelehem W., additional, Simmons, Dennis M., additional, Tse, Tonia E., additional, Lieu, Christopher H., additional, Davis, S. Lindsey, additional, Leal, Alexis D., additional, Diamond, Jennifer R., additional, Messersmith, Wells A., additional, and Pitts, Todd M., additional

Published
2019
Full Text
View/download PDF

44. Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer

Author

Jones, Jeremy C., primary, Renfro, Lindsay A., additional, Al-Shamsi, Humaid O., additional, Schrock, Alexa B., additional, Rankin, Andrew, additional, Zhang, Ben Y., additional, Kasi, Pashtoon M., additional, Voss, Jesse S., additional, Leal, Alexis D., additional, Sun, James, additional, Ross, Jeffrey, additional, Ali, Siraj M., additional, Hubbard, Joleen M., additional, Kipp, Benjamin R., additional, McWilliams, Robert R., additional, Kopetz, Scott, additional, Wolff, Robert A., additional, and Grothey, Axel, additional

Published
2017
Full Text
View/download PDF

46. NCCTG N08CA (Alliance): The use of Glutathione for Prevention of Paclitaxel/Carboplatin Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo-Controlled Study

Author

Leal, Alexis D., Qin, Rui, Atherton, Pamela J., Haluska, Paul, Behrens, Robert J., Tiber, Charles, Watanaboonyakhet, Patanit, Weiss, Matthias, Adams, Paul T., Dockter, Travis, and Loprinzi, Charles L.

Subjects
Male, Placebos, Double-Blind Method, Paclitaxel, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Peripheral Nervous System Diseases, Female, Middle Aged, Glutathione, Article, Carboplatin
Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of taxane and platinum-based chemotherapy. Several studies have supported the potential benefit of glutathione for the prevention of platinum-induced CIPN. The current trial was designed to determine whether glutathione would prevent CIPN as a result of carboplatin/paclitaxel therapy.In total, 185 patients who received treatment with paclitaxel and carboplatin were accrued between December 4, 2009 and December 19, 2011. Patients were randomized to receive either placebo (n = 91) or 1.5 g/m(2) glutathione (n = 94) over 15 minutes immediately before chemotherapy. CIPN was assessed using the European Organization for Research and Treatment of Cancer Quality-of-Life (EORTC-QLQ) 20-item, CIPN-specific (CIPN20) sensory subscale and the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.There were no statistically significant differences between the 2 study arms with regard to: 1) peripheral neurotoxicity, as assessed using both the EORTC-QLQ-CIPN20 (P = .21) and the CTCAE scales (P = .449 for grade ≥2 neurotoxicity; P = .039 for time to development of grade ≥2 neuropathy, in favor of the placebo); 2) the degree of paclitaxel acute pain syndrome (P = .30 for patients who received paclitaxel every 3-4 weeks and P = .002, in favor of the placebo, for patients who received weekly paclitaxel); 3) the time to disease progression (P = .63); or 4) apparent toxicities. Subgroup analyses did not reveal any evidence of benefit in any particular subgroup.The results from this study do not support the use of glutathione for the prevention of paclitaxel/carboplatin-induced CIPN.

Published
2014

48. Variability of performance status assessment between patients with hematologic malignancies and their physicians.

Author

Leal, Alexis D., Allmer, Cristine, Maurer, Matthew J., Shanafelt, Tait D., Cerhan, James R., Link, Brian K., and Thompson, Carrie A.

Subjects
*LYMPHOBLASTIC leukemia treatment, *HEMATOPOIETIC system, *IMMUNOLOGIC diseases, *T-cell lymphoma, *HEMATOLOGIC malignancies
Abstract

This study was conducted to determine the incidence of inter-observer variability in Eastern Cooperative Oncology Group (ECOG) performance status (PS) rating between patients with leukemia and lymphoma and their physicians. ECOG PS was assessed at diagnosis by patients and their physicians and stratified by disease subtype, gender, age, disease stage and education. Association between patient- and physician-rated PS and overall survival (OS) was stratified by subtype and prognostic risk score. Overall, 65% of patients and physicians rated PS the same. Age, disease stage and disease subtype were significant predictors of PS disagreement. PS was a significant predictor of OS irrespective of assessment by patients or physicians across all subtypes except those with Hodgkin lymphoma. These findings suggest the need for physicians to better communicate with patients when determining PS, as PS is a strong predictor of survival and is critical in treatment decisions, including determining fitness for cancer treatment. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

50. Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors

Author

Rausch Osian, Sarah, primary, Leal, Alexis D., additional, Allmer, Cristine, additional, Maurer, Matthew J., additional, Nowakowski, Grezegorz, additional, Inwards, David J., additional, Macon, William R., additional, Ehlers, Shawna L., additional, Weiner, George J., additional, Habermann, Thomas M., additional, Cerhan, James R., additional, and Thompson, Carrie A., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results